http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2779484-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_68c213ba9952360f439567152e047b18 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-4703 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-56 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5743 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N35-00 |
| filingDate | 2010-10-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_75f3a46e9a8ddedaba21f9af60f73590 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_576903801fdd451fcb56233d54347039 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_189928a95ffe1c87d51cc5df83306cce http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fe16b787f42058999e94061a39300091 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_70135fd9709dd6d124074c67c5696d6c |
| publicationDate | 2011-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CA-2779484-A1 |
| titleOfInvention | A melanoma prognostic model using tissue microarrays and genetic algorithms |
| abstract | Provided is a method for determining the risk that a patient diagnosed with melanoma will develop a recurrence of melanoma comprising: a) determining the level of expression for each marker of a panel of markers, wherein the panel comprises activating transcription factor 2, p21V1AF1, p16NK4A, beta-catenin, and fibronectin and the levels of expression are determined in compartments of interest in a tumor tissue sample from the patient; and b) determining whether an expression parameter for each marker in the tumor tissue sample is achieved by comparing the level of expression of each marker with a predetermined reference level associated with each marker; wherein the patient is at a low risk of developing a recurrence of melanoma if four or more of the expression parameters are achieved and is at a high risk of developing a recurrence of melanoma if three or fewer of the expression parameters are achieved. |
| priorityDate | 2009-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 196.